HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.

Abstract
Arginase deficiency is caused by deficiency of arginase 1 (ARG1), a urea cycle enzyme that converts arginine to ornithine. Clinical features of arginase deficiency include elevated plasma arginine levels, spastic diplegia, intellectual disability, seizures and growth deficiency. Unlike other urea cycle disorders, recurrent hyperammonemia is typically less severe in this disorder. Normalization of plasma arginine levels is the consensus treatment goal, because elevations of arginine and its metabolites are suspected to contribute to the neurologic features. Using data from patients enrolled in a natural history study conducted by the Urea Cycle Disorders Consortium, we found that 97% of plasma arginine levels in subjects with arginase deficiency were above the normal range despite conventional treatment. Recently, arginine-degrading enzymes have been used to deplete arginine as a therapeutic strategy in cancer. We tested whether one of these enzymes, a pegylated human recombinant arginase 1 (AEB1102), reduces plasma arginine in murine models of arginase deficiency. In neonatal and adult mice with arginase deficiency, AEB1102 reduced the plasma arginine after single and repeated doses. However, survival did not improve likely, because this pegylated enzyme does not enter hepatocytes and does not improve hyperammonemia that accounts for lethality. Although murine models required dosing every 48 h, studies in cynomolgus monkeys indicate that less frequent dosing may be possible in patients. Given that elevated plasma arginine rather than hyperammonemia is the major treatment challenge, we propose that AEB1102 may have therapeutic potential as an arginine-reducing agent in patients with arginase deficiency.
AuthorsLindsay C Burrage, Qin Sun, Sarah H Elsea, Ming-Ming Jiang, Sandesh C S Nagamani, Arthur E Frankel, Everett Stone, Susan E Alters, Dale E Johnson, Scott W Rowlinson, George Georgiou, Members of Urea Cycle Disorders Consortium, Brendan H Lee
JournalHuman molecular genetics (Hum Mol Genet) Vol. 24 Issue 22 Pg. 6417-27 (Nov 15 2015) ISSN: 1460-2083 [Electronic] England
PMID26358771 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Copyright© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected].
Chemical References
  • Recombinant Proteins
  • Arginine
  • Arginase
Topics
  • Animals
  • Arginase (blood, genetics, therapeutic use)
  • Arginine (blood, metabolism)
  • Brain (metabolism)
  • Child
  • Child, Preschool
  • Cohort Studies
  • Disease Models, Animal
  • Female
  • Humans
  • Hyperammonemia (blood, metabolism)
  • Hyperargininemia (blood, drug therapy, genetics, metabolism)
  • Longitudinal Studies
  • Macaca fascicularis
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Recombinant Proteins (therapeutic use)
  • Seizures (blood, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: